{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:14Z","timestamp":1786982114712,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:00:00Z","timestamp":1445385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11883-015-0552-3","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T04:24:57Z","timestamp":1445401497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Statin Intolerance: the Clinician\u2019s Perspective"],"prefix":"10.1007","volume":"17","author":[{"given":"Tom\u00e1\u0161","family":"Stulc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ce\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Antonio M.","family":"Gotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,21]]},"reference":[{"issue":"9753","key":"552_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"5","key":"552_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472\u201383.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"552_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"552_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96\u2013103.","journal-title":"Circulation"},{"issue":"3 Suppl","key":"552_CR5","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","volume":"8","author":"JR Guyton","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72\u201381.","journal-title":"J Clin Lipidol"},{"issue":"3 Suppl","key":"552_CR6","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58\u201371.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"552_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11883-014-0475-4","volume":"17","author":"MA Cornier","year":"2015","unstructured":"Cornier MA, Eckel RH. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? Curr Atheroscler Rep. 2015;17(2):475.","journal-title":"Curr Atheroscler Rep"},{"issue":"3 Suppl","key":"552_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47\u201357.","journal-title":"J Clin Lipidol"},{"issue":"3 Suppl","key":"552_CR9","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","volume":"8","author":"CH Rojas-Fernandez","year":"2014","unstructured":"Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V, The National Lipid Association's Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S5\u201316.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"552_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11883-014-0458-5","volume":"16","author":"T Stulc","year":"2014","unstructured":"Stulc T, Ceska R. Statins, glycemia, and diabetes mellitus: another point of view. Curr Atheroscler Rep. 2014;16(12):458.","journal-title":"Curr Atheroscler Rep"},{"issue":"17","key":"552_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"key":"552_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","volume":"29","author":"GB Mancini","year":"2013","unstructured":"Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553\u201368.","journal-title":"Can J Cardiol"},{"issue":"5","key":"552_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11886-015-0582-z","volume":"17","author":"A Pirillo","year":"2015","unstructured":"Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. Curr Cardiol Rep. 2015;17(5):582.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"552_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jama.2015.1335","volume":"313","author":"CB Newman","year":"2015","unstructured":"Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA. 2015;313(10):1011\u20132.","journal-title":"JAMA"},{"issue":"1","key":"552_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MOL.0000000000000149","volume":"26","author":"D Preiss","year":"2015","unstructured":"Preiss D, Sattar N. Classification of reported statin intolerance. Curr Opin Lipidol. 2015;26(1):65\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"552_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1\u201323.","journal-title":"Arch Med Sci"},{"key":"552_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526\u201334.","journal-title":"Ann Intern Med"},{"key":"552_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597\u2013603.","journal-title":"Am Heart J"},{"issue":"4","key":"552_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","volume":"8","author":"CD Robison","year":"2014","unstructured":"Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol. 2014;8(4):401\u20137.","journal-title":"J Clin Lipidol"},{"key":"552_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.mehy.2011.07.007","volume":"77","author":"CJ Glueck","year":"2011","unstructured":"Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses. 2011;77:658\u201361.","journal-title":"Med Hypotheses"},{"issue":"2","key":"552_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","volume":"238","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329\u201335.","journal-title":"Atherosclerosis"},{"issue":"1","key":"552_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","volume":"90","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24\u201334.","journal-title":"Mayo Clin Proc"},{"key":"552_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.amjcard.2007.03.059","volume":"100","author":"JM Backes","year":"2007","unstructured":"Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007;100:554\u20135.","journal-title":"Am J Cardiol"},{"key":"552_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","volume":"103","author":"JF Ruisinger","year":"2009","unstructured":"Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009;103:393\u20134.","journal-title":"Am J Cardiol"},{"key":"552_CR25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","volume":"101","author":"M Gadarla","year":"2008","unstructured":"Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101:1747\u20138.","journal-title":"Am J Cardiol"},{"key":"552_CR26","unstructured":"Honkanen M. Managing the statin-intolerant patient: low-dose\/low-frequency treatment regimens. LipidSpin 2013; 11(4): 9\u201312. \n                    https:\/\/www.lipid.org\/communications\/lipid_spin\/lipid-spin-fall-2013\n                    \n                  . Accessed June 1, 2015"},{"key":"552_CR27","unstructured":"Cannon CP, on behalf of the IMPROVE IT Investigators. IMPROVE-IT Trial: A comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Presented at: American heart Association Scientific Sessions: Late-braking clinical trials: Anti-Lipid Therapy and Prevention of CAD, November 17, 2014. \n                    http:\/\/my.americanheart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/@scon\/documents\/downloadable\/ucm_469598.pdf\n                    \n                  . Accessed June 1, 2015"},{"issue":"9729","key":"552_CR28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875\u201384.","journal-title":"Lancet"},{"issue":"3","key":"552_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312.","journal-title":"N Engl J Med"},{"key":"552_CR30","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"issue":"16","key":"552_CR31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139.","journal-title":"N Engl J Med"},{"key":"552_CR32","unstructured":"Robinson JG et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients. . Presented at: ESC Congress 2014, Hot Line session: Coronary artery disease and lipids, 31 August 2014. \n                    http:\/\/www.escardio.org\/Congresses-&-Events\/Congress-resources\/ESC-Congress-365\/Long-term-safety-tolerability-and-efficacy-of-alirocumab-versus-placebo-in-high\n                    \n                  ."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-015-0552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-015-0552-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-015-0552-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-015-0552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T20:41:18Z","timestamp":1581972078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-015-0552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s11883-015-0552-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]},"assertion":[{"value":"21 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tom\u00e1\u0161 \u0160tulc and Richard \u010ce\u0161ka declare that they have no conflict of interest.Antonio M. Gotto Jr. declares personal fees from Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, DuPont, Esperion Therapeutics, KOWA, Merck, Roche, Vatera Capital, and ISIS Pharmaceuticals for various boards of directors, advisory boards, consultancies, and data safety monitoring board duties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"69"}}